Table of Content



1. Research Scope & Methodology
1.1. Study Objectives
1.2. Methodology
1.3. Assumptions & Limitations

2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview
2.3. Scope Of Study
2.4. Crisis Scenario Analysis
2.4.1. Impact Of Covid-19 On Ophthalmic Drugs Market
2.5. Major Market Findings
2.5.1. Emerging Therapies For Dry Eye Syndrome
2.5.2. Growing Demand For Combination Therapies
2.5.3. Increasing Investment In Research & Development
2.5.4. Shift Toward Over-The-Counter (Otc) Products

3. Market Dynamics
3.1. Key Drivers
3.1.1. Aging Population’S Susceptibility To Age-Related Eye Conditions
3.1.2. Advancements In Drug Delivery Technologies
3.1.3. Rising Prevalence Of Eye Diseases And Disorders
3.1.4. Favorable Reimbursement Policies By Healthcare Systems
3.2. Key Restraints
3.2.1. Delay In Drug Approvals
3.2.2. Side Effects Related To Ophthalmic Drugs

4. Key Analytics
4.1. Key Market Trends
4.2. Technology Snapshot
4.2.1. Biologics
4.2.2. Cell Therapy
4.2.3. Gene Therapy
4.2.4. Drug Delivery
4.2.5. Small Molecule
4.2.6. Other Technologies
4.3. Porter’S Five Forces Analysis
4.3.1. Buyers Power
4.3.2. Suppliers Power
4.3.3. Substitution
4.3.4. New Entrants
4.3.5. Industry Rivalry
4.4. Growth Prospect Mapping
4.5. Market Maturity Analysis
4.6. Market Concentration Analysis
4.7. Key Buying Criteria
4.8. Regulatory Framework

5. Market By Indication
5.1. Dry Eye
5.2. Glaucoma
5.3. Infection/Inflammation/Allergies
5.4. Retinal Disorder
5.4.1. Wet Age-Related Macular Degeneration
5.4.2. Dry Age-Related Macular Degeneration
5.4.3. Diabetic Retinopathy
5.4.4. Other Retinal Disorders
5.5. Other Indications

6. Market By Type
6.1. Prescription Drugs
6.2. Over-The-Counter Drugs

7. Market By Dosage Form
7.1. Gels
7.2. Eye Solutions & Suspensions
7.3. Capsules & Tablets
7.4. Eye Drops
7.5. Ointments

8. Market By Therapeutic Class
8.1. Anti-Glaucoma
8.2. Anti-Infection
8.3. Anti-Inflammatory
8.4. Anti-Allergy
8.5. Other Therapeutic Classes

9. Market By Distribution Channel
9.1. Hospital Pharmacies
9.2. Drug Stores
9.3. Online Pharmacies
9.4. Other Distribution Channels

10. Geographical Analysis
10.1. North America
10.1.1. Market Size & Estimates
10.1.2. North America Ophthalmic Drugs Market Drivers
10.1.3. North America Ophthalmic Drugs Market Challenges
10.1.4. Key Players In North America Ophthalmic Drugs Market
10.1.5. Country Analysis
10.1.5.1. United States
10.1.5.1.1. United States Ophthalmic Drugs Market Size & Opportunities
10.1.5.2. Canada
10.1.5.2.1. Canada Ophthalmic Drugs Market Size & Opportunities

11. Competitive Landscape
11.1. Key Strategic Developments
11.1.1. Mergers & Acquisitions
11.1.2. Product Launches & Developments
11.1.3. Partnerships & Agreements
11.2. Company Profiles
11.2.1. Abbvie Inc
11.2.1.1. Company Overview
11.2.1.2. Products & Services
11.2.1.3. Strengths & Challenges
11.2.2. Accutome Inc
11.2.2.1. Company Overview
11.2.2.2. Products & Services
11.2.2.3. Strengths & Challenges
11.2.3. Bausch Health Companies Inc
11.2.3.1. Company Overview
11.2.3.2. Products & Services
11.2.3.3. Strengths & Challenges
11.2.4. Genentech Inc
11.2.4.1. Company Overview
11.2.4.2. Products & Services
11.2.4.3. Strengths & Challenges
11.2.5. Johnson & Johnson
11.2.5.1. Company Overview
11.2.5.2. Products & Services
11.2.5.3. Strengths & Challenges
11.2.6. Thea Pharma Inc
11.2.6.1. Company Overview
11.2.6.2. Products & Services
11.2.6.3. Strengths & Challenges
11.2.7. Novartis Ag
11.2.7.1. Company Overview
11.2.7.2. Products & Services
11.2.7.3. Strengths & Challenges
11.2.8. Pfizer Inc
11.2.8.1. Company Overview
11.2.8.2. Products & Services
11.2.8.3. Strengths & Challenges
11.2.9. Regeneron Pharmaceuticals Inc
11.2.9.1. Company Overview
11.2.9.2. Products & Services
11.2.9.3. Strengths & Challenges
11.2.10. Santen Pharmaceutical Co Ltd
11.2.10.1. Company Overview
11.2.10.2. Products & Services
11.2.10.3. Strengths & Challenges
11.2.11. Sun Pharmaceutical Industries Ltd
11.2.11.1. Company Overview
11.2.11.2. Products & Services
11.2.11.3. Strengths & Challenges
11.2.12. Teva Pharmaceuticals Industries Ltd
11.2.12.1. Company Overview
11.2.12.2. Products & Services
11.2.12.3. Strengths & Challenges



List of Figures

List Of Figures
Figure 1: Key Market Trends
Figure 2: Porter’S Five Forces Analysis
Figure 3: Growth Prospect Mapping
Figure 4: Market Maturity Analysis
Figure 5: Market Concentration Analysis
Figure 6: North America Ophthalmic Drugs Market, Growth Potential, By Indication, In 2022
Figure 7: North America Ophthalmic Drugs Market, By Dry Eye, 2023-2032 (In $ Million)
Figure 8: North America Ophthalmic Drugs Market, By Glaucoma, 2023-2032 (In $ Million)
Figure 9: North America Ophthalmic Drugs Market, By Infection/Inflammation/Allergies, 2023-2032 (In $ Million)
Figure 10: North America Ophthalmic Drugs Market, By Retinal Disorder, 2023-2032 (In $ Million)
Figure 11: North America Ophthalmic Drugs Market, Growth Potential, By Retinal Disorder, In 2022
Figure 12: North America Ophthalmic Drugs Market, By Wet Age-Related Macular Degeneration, 2023-2032 (In $ Million)
Figure 13: North America Ophthalmic Drugs Market, By Dry Age-Related Macular Degeneration, 2023-2032 (In $ Million)
Figure 14: North America Ophthalmic Drugs Market, By Diabetic Retinopathy, 2023-2032 (In $ Million)
Figure 15: North America Ophthalmic Drugs Market, By Other Retinal Disorders, 2023-2032 (In $ Million)
Figure 16: North America Ophthalmic Drugs Market, By Other Indications, 2023-2032 (In $ Million)
Figure 17: North America Ophthalmic Drugs Market, Growth Potential, By Type, In 2022
Figure 18: North America Ophthalmic Drugs Market, By Prescription Drugs, 2023-2032 (In $ Million)
Figure 19: North America Ophthalmic Drugs Market, By Over-The-Counter Drugs, 2023-2032 (In $ Million)
Figure 20: North America Ophthalmic Drugs Market, Growth Potential, By Dosage Form, In 2022
Figure 21: North America Ophthalmic Drugs Market, By Gels, 2023-2032 (In $ Million)
Figure 22: North America Ophthalmic Drugs Market, By Eye Solutions & Suspensions, 2023-2032 (In $ Million)
Figure 23: North America Ophthalmic Drugs Market, By Capsules & Tablets, 2023-2032 (In $ Million)
Figure 24: North America Ophthalmic Drugs Market, By Eye Drops, 2023-2032 (In $ Million)
Figure 25: North America Ophthalmic Drugs Market, By Ointments, 2023-2032 (In $ Million)
Figure 26: North America Ophthalmic Drugs Market, Growth Potential, By Therapeutic Class, In 2022
Figure 27: North America Ophthalmic Drugs Market, By Anti-Glaucoma, 2023-2032 (In $ Million)
Figure 28: North America Ophthalmic Drugs Market, By Anti-Infection, 2023-2032 (In $ Million)
Figure 29: North America Ophthalmic Drugs Market, By Anti-Inflammatory, 2023-2032 (In $ Million)
Figure 30: North America Ophthalmic Drugs Market, By Anti-Allergy, 2023-2032 (In $ Million)
Figure 31: North America Ophthalmic Drugs Market, By Other Therapeutic Classes, 2023-2032 (In $ Million)
Figure 32: North America Ophthalmic Drugs Market, Growth Potential, By Distribution Channel, In 2022
Figure 33: North America Ophthalmic Drugs Market, By Hospital Pharmacies, 2023-2032 (In $ Million)
Figure 34: North America Ophthalmic Drugs Market, By Drug Stores, 2023-2032 (In $ Million)
Figure 35: North America Ophthalmic Drugs Market, By Online Pharmacies, 2023-2032 (In $ Million)
Figure 36: North America Ophthalmic Drugs Market, By Other Distribution Channels, 2023-2032 (In $ Million)
Figure 37: North America Ophthalmic Drugs Market, Country Outlook, 2022 & 2032 (In %)
Figure 38: United States Ophthalmic Drugs Market, 2023-2032 (In $ Million)
Figure 39: Canada Ophthalmic Drugs Market, 2023-2032 (In $ Million)

List of Tables

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – OPHTHALMIC DRUGS
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY INDICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 4: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY INDICATION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 5: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 6: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 7: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 8: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 9: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 10: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 11: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 12: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 13: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 14: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 15: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 16: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 17: KEY PLAYERS OPERATING IN NORTH AMERICA OPHTHALMIC DRUGS MARKET
TABLE 18: LIST OF MERGERS & ACQUISITIONS
TABLE 19: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 20: LIST OF PARTNERSHIPS & AGREEMENTS